LDS/Medical Tests/Cotinine, Urine

Cotinine, Urine

Smoking and tobacco usage predisposes individuals and society at large to a variety of health problems, including peripheral vascular disease, coronary artery disease, stroke and lung cancer. Smoking cessation programs are aimed at minimizing these risks and promoting an active lifestyle. Compliance with smoking cessation programs, detection of second-hand smoke exposure, environmental tobacco exposure and minimizing withdrawal symptoms by use of nicotine substitutes is now improved by laboratory detection and quantification of tobacco/nicotine exposure.

Nicotine, an active substance in cigarettes and other tobacco products, is an alkaloid which stimulates the autonomic nervous system (increases heart rate, blood pressure etc.), psychoactive centers (euphoria, relaxation, reduced pain, and anxiety) and endogenous reward system in the brain (habit forming behavior). Nicotine is rapidly metabolized in the liver (half-life = 2 hrs) to primarily cotinine and other minor primary and secondary metabolites. A portion of cotinine is conjugated while most of it is excreted unchanged in the urine. The half-life of cotinine is much longer (14-16 hrs) than nicotine and the concentrations are stable throughout the day which makes it a surrogate marker for nicotine exposure.

The concentration of cotinine in urine is 4-6 times higher than in blood and other body fluids and is directly proportional to the nicotine dose and inversely proportional to the liver catabolic activity which itself is partially determined by genetics. Anabasine is a chemical substance that is found in tobacco products but not in manufactured therapeutic nicotine substitutes. Hence, detection of anabasine almost always indicates cigarette smoking and/or other tobacco product usage. Quantitative analysis of cotinine in the urine may help differentiate active tobacco use, abstinence, second-hand smoke exposure and tobacco non-exposure.

  • To document tobacco use (various medical indications)
  • To document abstinence from tobacco/smoking cessation
  • To assess adequacy of nicotine replacement therapy
  • To detect second-hand smoke exposure (pregnant women and children)
  • Rarely, to diagnose acute nicotine toxicity and accidental nicotine poisoning in children (by nicotine substitutes)

Urine cotinine:

  • Non-exposure
  • Second hand smoke exposure
  • Two-week abstinence in heavy smokers
  • Active smokers 1,000-8,000 ng/ml

Blood cotinine:

  • Non-exposure
  • Second hand smoke exposure
  • Two-week abstinence in smokers
  • Active smokers 200-800 ng/ml

Urine cotinine < 5 ng/ml
Blood cotinine < 2 ng/ml

High performance liquid chromatography/tandem mass spectrometry (LC-MS/MS). Cotinine is extracted from the urine/blood by solid-phase extraction techniques. The eluate is subjected to LC-MS/MS for detection and quantification of cotinine.

Urine

Random urine sample — collect at least 3 ml of urine in a clean container without preservatives and transport to the lab at ambient/refrigerated temperatures.

Blood

Collect 5 ml of venous blood in a red top tube (serum). Transport to the laboratory at refrigerated temperatures.

Stability

  • Ambient: 2-5 days
  • Refrigerated: 7 days
Blood/Urine anabasine may be required if there is a clinical concern to differentiate smoking/tobacco use from nicotine replacement therapy.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login